RIPA-56 is primarily used as a potent and selective inhibitor of RIP1 kinase (Receptor-Interacting Protein 1), making it a valuable tool in research related to programmed cell death pathways, particularly necroptosis. It is widely applied in cellular and molecular studies to dissect the role of RIP1 in inflammatory diseases, neurodegenerative disorders, and cancer. Due to its high selectivity, RIPA-56 helps researchers modulate necroptotic signaling without affecting related kinases excessively, allowing for clearer interpretation of experimental outcomes. It is commonly used in in vitro models such as primary neurons, immune cells, and various cancer cell lines to assess cell viability, cytokine production, and signaling pathway modulation. Its application also extends to preclinical studies exploring therapeutic strategies where inhibition of aberrant cell death and inflammation is critical.